Fig. 4: Targeting the PI3K/Akt/mTOR pathway with BEZ235 yielded best antitumor effects in PTX-resistant GC cells. | Cell Death & Disease

Fig. 4: Targeting the PI3K/Akt/mTOR pathway with BEZ235 yielded best antitumor effects in PTX-resistant GC cells.

From: Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway

Fig. 4: Targeting the PI3K/Akt/mTOR pathway with BEZ235 yielded best antitumor effects in PTX-resistant GC cells.

a Significantly enriched pathways in PTX-resistant HGC-27R cells compared with parental cells identified through KEEG analysis. b Western blot quantification of protein expression in parental and PTX-resistant GC cells. c Cell viability and protein expression of parental cells and their resistant clones assayed by CCK-8 assay and western blot, respectively. Data expressed as mean ± S.D. of three independent experiments. *p < 0.05

Back to article page